Zhenying Tan‐Wasielewski

TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker

Erica L. Mayer, Vandana G. Abramson, Rachel C. Jankowitz et al. · Annals of Oncology · 2020 · 80 citations · Full text

Medicine, Molecular Biology, Oncology +14

A Phase II Study of Pembrolizumab in Combination With Palliative Radiotherapy for Hormone Receptor-positive Metastatic Breast Cancer

Romualdo Barroso‐Sousa, Ian E. Krop, Lorenzo Trippa et al. · Clinical Breast Cancer · 2020 · 76 citations

Medicine, Oncology, Radiation Oncology +16

Phase I dose-escalation trial of tucatinib in combination with trastuzumab in patients with HER2-positive breast cancer brain metastases

José Pablo Leone, T. Li, Zhenying Tan‐Wasielewski et al. · Annals of Oncology · 2020 · 46 citations · Full text

Medicine, Oncology, Pharmacology +17

Ribociclib Plus Trastuzumab in Advanced HER2-Positive Breast Cancer: Results of a Phase 1b/2 Trial

Shom Goel, Sònia Pernas, Zhenying Tan‐Wasielewski et al. · Clinical Breast Cancer · 2019 · 35 citations

Medicine, Oncology, Pharmacology +16

Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer

Elizabeth K. Lee, Zhenying Tan‐Wasielewski, Ursula A. Matulonis et al. · Gynecologic Oncology Reports · 2019 · 23 citations · Full text

Medicine, Oncology, Pharmacology +15